| Literature DB >> 35495688 |
Sudha Bind1, Sandhya Bind1, A K Sharma1, Preeti Chaturvedi1.
Abstract
Microorganisms are stupendous source of secondary metabolites, having significant pharmaceutical and industrial importance. Genome mining has led to the detection of several cryptic metabolic pathways in the natural producer of secondary metabolites (SMs) such as actinobacteria and fungi. Production of these bioactive compounds in considerable amount is, however, somewhat challenging. This led to the search of using epigenetics as a key mechanism to alter the expression of genes that encode the SMs toward higher production in microorganisms. Epigenetics is defined as any heritable change without involving the changes in the underlying DNA sequences. Epigenetic modifications include chromatin remodeling by histone posttranslational modifications, DNA methylation, and RNA interference. Biosynthetic gene cluster for SMs remains in heterochromatin state in which the transcription of constitutive gene is regulated by epigenetic modification. Therefore, small-molecule epigenetic modifiers, which promote changes in the structure of chromatin, could control the expression of silent genes and may be rationally employed for discovery of novel bioactive compounds. This review article focuses on the types of epigenetic modifications and their impact on gene expression for enhancement of SM production in microorganisms.Entities:
Keywords: biosynthetic gene cluster; chromatin remodeling; epigenetics; heritable changes; secondary metabolites
Year: 2022 PMID: 35495688 PMCID: PMC9043899 DOI: 10.3389/fmicb.2022.784109
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 6.064
FIGURE 1The impact of chromatin structure on transcriptional regulation of secondary metabolite (SM) gene clusters. SM gene clusters remain in transcriptionally inactive or repressive heterochromatin state. Due to different environmental cues (light, temperature, pH, carbon, nitrogen, and iron), chromatin changes from heterochromatin state to euchromatin (transcriptionally active) state, thus activating the SM biosynthetic pathway.
FIGURE 2Epigenetic modulation showing DNA methylation: attachment of methyl group at 5′-carbon atom of cytosine ring.
FIGURE 3Inhibition of DNA methyltransferase (DNMTs) by using DNMT inhibitors. Azacytidine used as a DNMT inhibitor are base analogs that prevent the transfer of the methyl group to cytosine by incorporating into nucleic acid. Inhibitors covalently attach to nucleic acid and lead to a hypomethylated state and activation of repressed gene.
The effect of exposure of microorganisms to epigenetic drugs.
| Microorganisms | Epigenetic modifier | Induced compounds | References |
| 5-azacytidine | Lunalides A and B |
| |
|
| 5-azacytidine and suberoylanilide hydroxamic acid | Cladochromes A, B, D–F, and G and calphostin B |
|
|
| Suberoylanilide hydroxamic acid | Nigerone A |
|
|
| 5-azacytidine | Sclerotiorin, sclerotioramine, dechloroisochromophilone III, dechloroisochromophilone IV, ochrephilone, 6-(3E, 5E)-5,7-dimethyl-2-methylenenona-3,5-dienyl)-2,4-dihydroxy-3- methylbenzaldehyde, and atlantinones A and B |
|
| 5-AZA and SAHA | Alternariol, alternariol-5-O-methyl ether, 30-hydroxyalternariol-5-O-methyl ether, altenusin, tenuazonic acid, and altertoxin II |
| |
| 5-AZA and SAHA | VOCs, terpenes, primary and secondary alkanes, alkenes, organic acids, and benzene derivatives |
| |
|
| SBHA and RG-108 | Tenuipyrone |
|
| Suberohydroxamic acid | 5-butyl-6-oxo-1,6-dihydropyridine-2-carboxylic acid and 5-(but-9-enyl)-6-oxo-1,6-dihydropyridine-2-carboxylic acid |
| |
|
| SBHA | Production of structurally diverse chaetophenol and some new polycyclic skeletons |
|
|
| 5-azacytidine | 4,6-dihydroxy-7-hydroxymethyl-3-methoxymethylcoumarin |
|
|
| Nicotinamide | Chaetophenol G and cancrolides A and B |
|
| 5-AZA and SAHA | Production of three new eremophilane-type sesquiterpenes, (dihydrobipolaroxin B, C, and D) and new dihydrobipolaroxin analogue |
| |
| Suberoylanilide hydroxamic acid or 5-azacytidine | Isosulochrin |
| |
|
| Nicotinamide | Enhanced production of branched aliphatic and aromatic polyketides; production of new secondary metabolites (chaetophenol G and cancrolides A and B) |
|
| 5-AZA, SAHA | Enhanced production of VOCs, ergosterol, and xylaguaianol C |
| |
| SBHA and 5-AZA | Production of a new diphenylether-O-glycoside (1, diorcinol 3-O-a-D-ribofuranoside) |
| |
| Suberoylanilide hydroxamic acid | (10’S)-verruculide B and vermistatin dihydrovermistatin |
| |
|
| SAHA | Production of 2,4-dimethoxyphenol and diorcinol and a new biphenyl derivative versiperol A |
|
|
| SAHA | Production of 18 dihydroisocoumarins, including five unknown brominated and two chlorinated compounds |
|
|
| Nicotinamide | p-anisic acid, benzyl anisate, syringic acid, sinapic acid, acetosyringone, phenyl acetic acid, gentisaldehyde, and p-hydroxy benzaldehyde |
|
|
| Valproic acid | Cyclopentadecanolide, oxathiazole 2 thione, and pyrrolo[1,2-a]pyrazine-1,4-dione, hexahydro-3-(2 methyl), methyl 2,3-anhydro-4-6-O-benzylidenehexopyranoside |
|
(5-AZA- 5-azacytidine; SAHA- suberoylanilide hydroxamic acid; SBHA- suberohydroxamic acid).
FIGURE 4Epigenetic modulation showing histone acetylation mediated by histone acetyltransferase (HAT) and deacetylation mediated by histone deacetylase (HDAC). HDAC inhibitors activate the silent gene by inhibiting the histone deacetylase. These labels are associated with chromatin modulation required for cryptic gene expression.